Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)

This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTC...

Descripción completa

Detalles Bibliográficos
Autores principales: Dioverti, Veronica, Boghdadly, Zeinab El, Shahid, Zainab, Waghmare, Alpana, Abidi, Maheen Z., Pergam, Steven, Boeckh, Michael, Dadwal, Sanjeet, Kamboj, Mini, Seo, Susan, Chemaly, Roy F., Papanicolaou, Genovefa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. 2022
Materias:
Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464362/
https://www.ncbi.nlm.nih.gov/pubmed/36103987
http://dx.doi.org/10.1016/j.jtct.2022.09.002
Descripción
Sumario:This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) and is an update of pervious publication. Since our original publication in 2020, the NIH and IDSA have published extensive guidelines for management of COVID-19 which are readily accessible ( NIH Guidelines , IDSA Guidelines ). This update focuses primarily on issues pertaining specifically to HCT/cellular therapy recipients. Information provided in this manuscript may change as new information becomes available.

Ejemplares similares